Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with advanced non-small cell lung cancer: Single center experience

被引:0
作者
Inal, A. [1 ]
Kucukoner, M.
Kaplan, M. A.
Urakci, Z.
Karakus, A. [2 ]
Komek, H. [3 ]
Dostbil, Z. [3 ]
Isikdogan, A.
机构
[1] Dicle Univ, Sch Med, Dept Med Oncol, Diyarbakir, Turkey
[2] Dicle Univ, Dept Internal Med, Diyarbakir, Turkey
[3] Dicle Univ, Dept Nucl Med, Diyarbakir, Turkey
来源
JOURNAL OF BUON | 2012年 / 17卷 / 04期
关键词
advanced non-small cell lung cancer; F-18 FDG PET; prognostic factors; PREDICTIVE FACTORS; SURVIVAL; CHEMOTHERAPY; RECURRENCE; IMPACT;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The purpose of this retrospective single-center study was to evaluate the prognostic implication on overall survival (OS) of the F-18 FDG PET scan in locally advanced or metastatic non small cell lung cancer (NSCLC) patients. Methods: We retrospectively reviewed 120 locally advanced or metastatic NSCLC patients (December 2004-November 2011) treated/followed at the Dicle University, School of Medicine, Department of Medical Oncology. SUVmax and other potential prognostic variables (n=18) were chosen for analysis. Univariate and multivariate analyses were conducted to identify prognostic factors for OS. Results: Among 18 variables of univariate analysis, 6 were identified to bear prognostic significance: sex (p=0.01), performance status (PS) (p=0.03), stage (p=0.04), bone metastases (p=0.002), serum albumin (p=0.01) and blood glucose level (p=0.03). Multivariate analysis showed that PS, bone metastases and serum albumin level were independent prognostic factors for OS (p=0.01, p=0.004, p=0.003, respectively). Conclusion: PS, serum albumin levels and bone metastases were independent prognostic factors, while FDG uptake of the primary lesion was not associated with prognosis of OS in locally advanced or metastatic NSCLC patients.
引用
收藏
页码:724 / 728
页数:5
相关论文
共 28 条
[1]   Cancer incidence and mortality in Europe, 2004 [J].
Boyle, P ;
Ferlay, J .
ANNALS OF ONCOLOGY, 2005, 16 (03) :481-488
[2]   Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results [J].
Breathnach, OS ;
Freidlin, B ;
Conley, B ;
Green, MR ;
Johnson, DH ;
Gandara, DR ;
O'Connell, M ;
Shepherd, FA ;
Johnson, BE .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1734-1742
[3]   Prognostic factors in non-small cell lung cancer - A decade of progress [J].
Brundage, MD ;
Davies, D ;
Mackillop, WJ .
CHEST, 2002, 122 (03) :1037-1057
[4]   SERUM-ALBUMIN AND OTHER PROGNOSTIC FACTORS RELATED TO RESPONSE AND SURVIVAL IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER [J].
ESPINOSA, E ;
FELIU, J ;
ZAMORA, P ;
BARON, MG ;
SANCHEZ, JJ ;
ORDONEZ, A ;
ESPINOSA, J .
LUNG CANCER, 1995, 12 (1-2) :67-76
[5]  
Giovacchini G, 2009, TUMORI J, V95, P177
[6]  
Gridelli C, 1999, JNCI-J NATL CANCER I, V91, P66
[7]   Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer [J].
Hellwig, D ;
Gröschel, A ;
Graeter, TP ;
Hellwig, AP ;
Nestle, U ;
Schäfers, HJ ;
Sybrecht, GW ;
Kirsch, CM .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (01) :13-21
[8]   Patient education level as a predictor of survival in lung cancer clinical trials [J].
Herndon, James E. ;
Kornblith, Alice B. ;
Holland, Jimmie C. ;
Paskett, Electra D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) :4116-4123
[9]  
Higashi K, 2002, J NUCL MED, V43, P39
[10]   Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma [J].
Hoang, Jenny K. ;
Hoagland, Luke F. ;
Coleman, R. Edward ;
Coan, April D. ;
Herndon, James E., II ;
Patz, Edward F., Jr. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1459-1464